核因子—κB在急性非淋巴细胞性白血病骨髓细胞中的表达及意义

Significance of nuclear factor-kB expression in MNC from acute myelogenous leukemia patients morrow

目的探讨核因子-κB(NF-κB)在初治与难治性急性非淋巴细胞性白血病骨髓细胞中的表达及意义。方法培养初治与难治急性非淋巴细胞性白血病患者骨髓单个核细胞,将两组病人细胞均分为试验组与对照组,试验组中加NF-κB抑制剂PDTC(终浓度为50μmol/L),对照组中不加PDTC直接培养。采用电泳迁移率分析(EMSA)法检测各组细胞NF-κB活化水平。结果难治组急性非淋巴细胞白血病细胞的NF-κB活化水平明显高于初治组;试验组细胞的NF-κB活化水平明显低于对照组。结论NF-κB活性水平增高可能与急性非淋巴细胞性白血病的发病及预后有关,PDTC能明显抑制NF-κB活化,因此可以考虑以NF-κB为治疗靶点以提高化疗效果。

[Objective] To investigate Significance of Nuclear Factor-kB expression in MNC from acute myelogenous leukemia patient morrow, [Methods] MNC from primary acute myelogenous leukemia and intractable acute myelogenous leukemia patients morrow were cultured. Divided MNC into inhibition group and contrast group, then add pyrroledithiocarbomate（PDTC） into inhibition group （last concentration is 50 μmol/L）. Using Electrophoretic Mobility Shift Assay（EMSA） test the expression of NF-κB. [Result] The expression of NF-kappa B（NF-κB） in intractable leukemia MNC is significandy higher than primary leukemia. The expression of NF-κB in inhibition group is significandy lower than contrast group. [Concluson] There are relation between the expression of NF-κB and the pathogenesis and prognosis of acute myelogenous leukemia. PDTC can significandy reduce the expression of NF-κB. In order to enhance efficiency of chemotherapy,we can consider to take NF-κB as a new therapeutic aim.